Allergan rises as Restasis patents renew investor faith
This article was originally published in Scrip
Executive Summary
Allergan's stock closed at $107.73 on 20 December, ending the week up 11.6% compared with the prior Friday, after the US Patent and Trademark Office (USPTO) issued notices of allowance for three new patents that could protect the company's dry eye drug Restasis (cyclosporine) from generic competition until 2024.